Roma Kaul

I have driven my career towards uncovering biological processes that go awry in diseases, with the aim of developing novel therapeutics and diagnostics. My educational training followed by experience in industry have allowed me to explore diverse sub-fields of cancer biology, cancer cachexia, and immunology which enables my multidimensional approach to problem solving. I am passionate about developing new therapeutics that aim to solve unmet medical needs.

• Harvard Extension School – Certificate in Drug Discovery and Drug Development
• Harvard Extension School – Certificate in Immuno-Oncology

• Old Drugs, new tricks: uncovering mechanisms of action of microtubule targeting agents in triple negative breast cancer., Invited speaker at Université Libre de Bruxelles, Brussels, Belgium, 2022
• Molecular context dictates the effects of eribulin on key EMT regulators: Snail and Slug, AACR Annual Meeting, Atlanta, 2019
• Eribulin disrupts TGF-β-mediated Smad2/3-dependent transcription of EMT promoting proteins in triple negative breast cancer cells, AACR Annual Meeting, Chicago, 2018
• Eribulin rapidly impairs TGF-β signaling, AACR Annual Meeting, Philadelphia, 2017
• Classic drugs wear new hats: interphase effects of microtubule targeting agents on oncogenic signaling pathways, Aspen Cancer Conference, Aspen, 2018
• Differential effects of eribulin on key transcription factors snail and slug, San Antonio Breast Cancer Symposium, San Antonio, 2018
• An approach to the identification of tumors driven by HER2 using the integrated activity of oncomiR miR-21 along with HER enriched genes, San Antonio Breast Cancer Symposium, San Antonio, 2013

• Fellow, Aspen Cancer Conference, Aspen, CO, 2018
• Presidential Ambassador Scholar, UT Health San Antonio, 2017
• Selected for Cancer Prevention and Research Institute of Texas (CPRIT) Predoctoral fellowship, 2017
• Outstanding student poster award, 26th Annual Pharmacology Graduate Student Symposium, UT Health San Antonio, 2016
• Outstanding student poster award, 26th Annual Pharmacology Graduate Student Symposium, UT Health San Antonio, 2015
• AVON-AACR International Scholar in Training Award, 36th Annual San Antonio Breast Cancer Symposium, 2013

• Takahashi et al. 3D Culture models with CRISPR screens reveal hyperactive NRF2 as a prerequisite for spheroid formation via regulation of proliferation and ferroptosis. Molecular Cell. 2020; 20 ;80(5):828- 844.e6.
• Nair MG et al. Epigenetic regulation of ER through mir18a identifies a poor prognostic subtype within ER positive HER-2 negative breast cancers. Cancer Medicine. 2020; 9(15): 5587–5597.
• Kaul R et al. Eribulin rapidly inhibits TGF-β-induced Snail expression and its effects on Slug identifies a potential biomarker of response. British Journal Cancer, 2019; 121, 611–621.
• Kaul R et al. Microtubule-Targeting Drugs: More than antimitotics. Journal of Natural Products, 2019; 82, 3, 680–685.
• Prabhu JS et al. Dissecting the biological heterogeneity within hormone receptor positive HER2 negative breast cancer by gene-expression markers identifies indolent tumors within late stage disease. Translational Oncology. 2017; 10(4): 699-706.
• Rohena C et al. Janus compounds, 5-Chloro-N4-methyl-N4-aryl-9H-pyrimido[4,5-b]indole-2,4-diamines, cause both microtubule depolymerizing and stabilizing effects. Molecules. 2016; 21(12): 1661.